FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2042639209> ?p ?o ?g. }

• W2042639209 endingPage "837" @default.
• W2042639209 startingPage "829" @default.
• W2042639209 abstract "Objective: Evaluate the lipid-altering effects of ezetimibe added to ongoing statin therapy, statin titration, switching from statin monotherapy to a more potent statin or to ezetimibe/simvastatin. Methods: A pooled analysis of patient-level data from 17 double-blind, active or placebo-controlled studies of 8667 hypercholesterolemic adults randomized to ezetimibe 10 mg added to ongoing statins, statin titration (doubling), or switching from ongoing statins to rosuvastatin (10 mg) or to ezetimibe/simvastatin (10/20 and 40 mg). Percent change from baseline in low-density lipoprotein cholesterol (LDL-C) was estimated by analysis of variance. Percent of patients who achieved LDL-C and other guideline-recommended targets, and target lipid levels by baseline distance to goal were evaluated. Results: LDL-C percent change from baseline was −26.0 for ezetimibe added to ongoing statin therapy, −27.6 for switching from ongoing statin to ezetimibe/simvastatin, −19.7 for switching to rosuvastatin 10 mg, and −9.7 for dose doubling of the ongoing statin. For patients within 0.8 mmol/L (30 mg/dL) of the target at baseline, LDL-C target attainment rates were 75.9% for adding ezetimibe to ongoing statin, 72.8% for switching to ezetimibe/simvastatin, 61.8% for switching to rosuvastatin, and 44.3% for statin dose-doubling. Similarly, improvements in other lipids and achievement of non-high-density lipoprotein cholesterol and apolipoprotein B targets among this patient group were largest for ezetimibe added to ongoing statins and switching to ezetimibe/simvastatin; switching to rosuvastatin 10 mg and statin dose-doubling were less effective. Conclusions: Adding ezetimibe to ongoing statin therapy appeared to be an effective option for patients who do not achieve lipid-lowering goals on statins alone." @default.
• W2042639209 created "2016-06-24" @default.
• W2042639209 creator A5023716582 @default.
• W2042639209 creator A5026256894 @default.
• W2042639209 creator A5030455530 @default.
• W2042639209 creator A5040420889 @default.
• W2042639209 creator A5090460841 @default.
• W2042639209 date "2014-12-01" @default.
• W2042639209 modified "2023-09-25" @default.
• W2042639209 title "Achieving goal lipid levels with ezetimibe plus statin add-on or switch therapy compared with doubling the statin dose. A pooled analysis" @default.
• W2042639209 cites W1502421189 @default.
• W2042639209 cites W1972054549 @default.
• W2042639209 cites W1973858585 @default.
• W2042639209 cites W1974768421 @default.
• W2042639209 cites W1976212953 @default.
• W2042639209 cites W1976358806 @default.
• W2042639209 cites W1977399475 @default.
• W2042639209 cites W1984387917 @default.
• W2042639209 cites W1992197441 @default.
• W2042639209 cites W1994618005 @default.
• W2042639209 cites W2001375687 @default.
• W2042639209 cites W2010505181 @default.
• W2042639209 cites W2024334311 @default.
• W2042639209 cites W2025041596 @default.
• W2042639209 cites W2043425870 @default.
• W2042639209 cites W2044203052 @default.
• W2042639209 cites W2052094004 @default.
• W2042639209 cites W2058444692 @default.
• W2042639209 cites W2059870401 @default.
• W2042639209 cites W2067236087 @default.
• W2042639209 cites W2076224130 @default.
• W2042639209 cites W2101102524 @default.
• W2042639209 cites W2118048840 @default.
• W2042639209 cites W2124186024 @default.
• W2042639209 cites W2136295087 @default.
• W2042639209 cites W2142264046 @default.
• W2042639209 cites W2142622210 @default.
• W2042639209 cites W2144790234 @default.
• W2042639209 cites W2149237513 @default.
• W2042639209 cites W2151969933 @default.
• W2042639209 cites W2152647023 @default.
• W2042639209 cites W2158014750 @default.
• W2042639209 cites W2158285675 @default.
• W2042639209 cites W2164089346 @default.
• W2042639209 cites W2164324917 @default.
• W2042639209 cites W2164551379 @default.
• W2042639209 cites W2165605025 @default.
• W2042639209 cites W2171860082 @default.
• W2042639209 cites W2410405995 @default.
• W2042639209 cites W3021842026 @default.
• W2042639209 cites W4211109054 @default.
• W2042639209 cites W4230870013 @default.
• W2042639209 doi "https://doi.org/10.1016/j.atherosclerosis.2014.10.105" @default.
• W2042639209 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25463129" @default.
• W2042639209 hasPublicationYear "2014" @default.
• W2042639209 type Work @default.
• W2042639209 sameAs 2042639209 @default.
• W2042639209 citedByCount "27" @default.
• W2042639209 countsByYear W20426392092015 @default.
• W2042639209 countsByYear W20426392092016 @default.
• W2042639209 countsByYear W20426392092017 @default.
• W2042639209 countsByYear W20426392092018 @default.
• W2042639209 countsByYear W20426392092019 @default.
• W2042639209 countsByYear W20426392092020 @default.
• W2042639209 countsByYear W20426392092021 @default.
• W2042639209 countsByYear W20426392092022 @default.
• W2042639209 countsByYear W20426392092023 @default.
• W2042639209 crossrefType "journal-article" @default.
• W2042639209 hasAuthorship W2042639209A5023716582 @default.
• W2042639209 hasAuthorship W2042639209A5026256894 @default.
• W2042639209 hasAuthorship W2042639209A5030455530 @default.
• W2042639209 hasAuthorship W2042639209A5040420889 @default.
• W2042639209 hasAuthorship W2042639209A5090460841 @default.
• W2042639209 hasConcept C126322002 @default.
• W2042639209 hasConcept C142724271 @default.
• W2042639209 hasConcept C204787440 @default.
• W2042639209 hasConcept C27081682 @default.
• W2042639209 hasConcept C2776329913 @default.
• W2042639209 hasConcept C2776839432 @default.
• W2042639209 hasConcept C2777482532 @default.
• W2042639209 hasConcept C2778163477 @default.
• W2042639209 hasConcept C2778657065 @default.
• W2042639209 hasConcept C2780499067 @default.
• W2042639209 hasConcept C71924100 @default.
• W2042639209 hasConcept C98274493 @default.
• W2042639209 hasConceptScore W2042639209C126322002 @default.
• W2042639209 hasConceptScore W2042639209C142724271 @default.
• W2042639209 hasConceptScore W2042639209C204787440 @default.
• W2042639209 hasConceptScore W2042639209C27081682 @default.
• W2042639209 hasConceptScore W2042639209C2776329913 @default.
• W2042639209 hasConceptScore W2042639209C2776839432 @default.
• W2042639209 hasConceptScore W2042639209C2777482532 @default.
• W2042639209 hasConceptScore W2042639209C2778163477 @default.
• W2042639209 hasConceptScore W2042639209C2778657065 @default.
• W2042639209 hasConceptScore W2042639209C2780499067 @default.
• W2042639209 hasConceptScore W2042639209C71924100 @default.
• W2042639209 hasConceptScore W2042639209C98274493 @default.
• W2042639209 hasFunder F4320307776 @default.

• next